for experts, there is the risk of a new epidemic

The experts gathered in Amsterdam to take stock of the fight against AIDS [VIDEO] sketch a morose image. In particular, they emphasize the decline of funding to fight against this infection. It should also be considered that the African countries most affected by the virus have a population surge that shows no sign of decline, so that there is the risk of a crisis that the institutions concerned might not to be able to manage. In fact, declining funding may jeopardize the progress made in recent years with the introduction of ARV by which the disease can be kept under control.

In 2016, the number of deaths due to AIDS fell for the first time below one million, in 2017 there was a further decline. However in the face of these declining mortality data, there has been a significant decline in funding to decrease the risk of a new pandemic in 2030. In particular, it is the risk predicted by the United Nations. United Nations, UNAIDS.

Still with regard to pharmaceutical research, especially by the giants of the large pharmaceutical industry, there is a worrying decline. On the other hand, the big pharmaceutical companies, according to their criteria, reduce and cut the funds for the research of new drugs intended mainly for the countries with fragile economy and thus can not guarantee an adequate economic return.

Another fear of experts also concerns a sharp drop in US subsidies. In particular, they fear that the cuts promised by the administration of Trump fight against AIDS but at the time still need to be approved by the US Congress.

Ndulu Kilonzo, who is part of the Kenya AIDS Control Council, points out that without appropriate investments, it will be very difficult to reach the targets set for 2030. In particular, investments are not Elimination of the virus, but also for prevention. . In this sense, enough to consider that funding to reduce the distribution of condoms in Africa

fight against HIV: research

Giuliano Rizzardini, Director of Infectious Diseases Dipartimeno Sacco Hospital in Milan, pointed out that the l 39; The introduction of antiretroviral drugs in the 1990s revolutionized the treatment of this condition. In particular, these molecules are able to interrupt the mechanisms used by the HIV virus to replicate and thus infect new cells.

However, if in the early 1990s, a person with HIV had to take 10-15 tablets a day, today, one tablet is enough. In the near future an additional advance in the treatment of HIV [VIDEO] will be represented by long-acting drugs, namely by long-acting molecules . In this sense, the infectiologist explains that the drugs will be taken by intramuscular injections, which are currently performed once a month or once every two months. In the future, it will be possible to extend the time between one injection and the other. These long-acting molecules are as effective as conventional antiretrovirals.